Article
GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF.
Leukemia - 1 Dec 1998
Rozemuller H, Terpstra W, Rombouts E J, Lawler M, Byrne C, FitzGerald D J, Kreitman R J, Wielenga J J, Löwenberg B, Touw I P, Hagenbeek A, Martens A C
Abstract excerpt
The severe combined immunodeficient (SCID) mouse model may be used to evaluate new approaches for the treatment of acute myeloid leukemia (AML). We have previously demonstrated the killing of SCID mouse leukemia initiating cells by in vitro incubation with human GM-CSF fused to Diphtheria toxin (DT-huGM-CSF). In this report, we show that in vivo treatment with DT-huGM-CSF eliminates AML growth in SCID mice. Seven...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.